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access to FP treatment and ensuring all patients of child-
bearing potential receive education at time of cancer diagnosis.
234
Raising the Bar of Oncofertility Care in HSCT Patients:
Implementation of an Oncofertility Education and
Referral Program
Hannah E. Spencer 1, Geoffrey Barkley 2, Laura P. Smith 3,
Gana Elizabeth Locker 4, Diana O. Rexrode 5, Amer Beitinjaneh 1,
Leonid Volodin 1, Lisa Huntsinger 6, Tamila L. Kindwall-Keller 1.
1 Hematology Oncology, University of Virginia School of
Medicine, Charlottesville, VA; 2 Stem Cell Transplant, University
of Virginia, Charlottesville, VA; 3 Reproductive Medicine and
Surgery Center of Virignia, Charlottesville, VA; 4 Stem Cell
Transplant, University of Virginia Health System,
Charlottesville, VA; 5 Stem Cell Transplant Program, University
of Virginia, Charlottesville, VA; 6 University of Virginia Health
System, Charlottesville, VA
Background: Hematopoietic stem cell transplant (HSCT) sur-
vivors and their partners frequently struggle with infertility
post HSCT, which can decrease quality of life (QOL). With an
increasing number of HSCT survivors, a systematic pre-trans-
plant and survivorship care plan that includes oncofertility is
eagerly needed. A comprehensive guideline on oncofertility
education and referral does not exist for HSCT patients.
Therefore, our HSCT program developed an Oncofertility Ed-
ucation and Referral Program (OERP) to empower HSCT phy-
sicians, nurses, and patients with knowledge of fertility
preservation (FP) and family planning options. The strategy
and tools of our OERP implementation can assist transplant
groups at other institutions in initiating similar programs.
Methods: A multidisciplinary team identiﬁed barriers that
providersexperience indeliveringoncofertilityeducation, and
dealing with programmatic barriers for referrals to repro-
ductive specialists. The American Society of Clinical Oncology
(ASCO) and National Comprehensive Cancer Network (NCCN)
guidelines on oncofertility education were used to develop
program-speciﬁc guidelines and educational material for
providers and patients. A referral network was built through
collaboration with local reproductive medicine specialists.
Results: OERP implementation occurred over a 12-month
period fromJuly2013 to July2014 (Figure1).Weput into service
a standard operating procedure (SOP) on FP Education and
Referral that incorporated ASCO and NCCN guidelines as
well as a referral algorithmwith contact information. Biannual
in-service oncofertility education sessions were provided to
HSCT physicians, nurses, and support staff. Provider educationFigure 1. Flow chart depicting strategy andpackets that include national guidelines, referral contacts,
and support services were made available on the shared drive
for anytime access. Patient education packets that contain a
one-page fact sheet, local reproductive medicine clinic
information, FP ﬁnancial assistance, and support services
were also made available on shared drive. Oncofertility
discussions were incorporated into programmatic patient care
committee meetings and patient intake education sessions to
ensure oncofertility education is delivered from the beginning
of patient care. A computer-based learning module was
created for continuing education and is undergoing
institutional review for implementation.
Conclusions: We created a comprehensive OERP for HSCT
providers and patients. Success of the OERPwill bemeasured
annually through reproductive specialist referral metrics and
surveys given periodically to patients and providers. In an
effort to improve HSCT survivors’ QOL, programs should
implement an OERP to ensure patients make informed de-
cisions concerning the future of their reproductive health
before undergoing HSCT.235
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Introduction: Long-term stable mixed chimerism (MC) is
rare after allogeneic hematopoietic stem cell transplantation
(HSCT). MC is deﬁned as 5-95% residual recipient hemato-
poietic cells beyond one-year post-HSCT. The mechanisms
directing hematopoietic recovery to MC in some patients and
to full donor chimerism (DC) in others are poorly understood.
Methods: We compared patients with DC and long-term
stable MC for a median of 9.5 years post-HSCT. Both the
clinical situation and the immune system (functional and
phenotypic properties) were investigated by questionnaires,
western blot, multiplex bead-based immunoassay, ELISA and
ﬂow cytometry. Blood samples were drawn at 2 weeks and
>5 years post-HSCT. Additionally, lineage-speciﬁc chimerism
status in the MC patients was determined. The results were
analyzed by the Mann-Whitney U test, Fisher’s exact test and
Spearman’s rank correlation coefﬁcient.processes of OERP implementation.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S171eS184 S183Results: At two weeks post-HSCT cytokine levels did not
differ between the groups. Neither did the groups differ in
long-term outcome in terms of general wellbeing, immu-
noglobulin response to vaccinations and in the most central
phenotypic features of the immune system (e.g., differenti-
ation status, CD4/CD8 ratio, B and NK cell frequency). More
than 5 years post-HSCT, MC patients had signiﬁcantly higher
NKT cell levels (CD94+CD8+ and CD56+CD8+ T cells) than DC
patients. In-depth analysis of the MC patients revealed that
recipient chimerism could be observed in a large variety of
immune cell lineages (i.e., total, CD4+, CD8+ and gd T cells; B
cells; NK cells; myeloid cells; and cytokine producing cells).
Furthermore, the recipient chimerism in different cell line-
ages were positively correlated with each other, e.g., an in-
crease in CD3 chimerism was associated to an increase in
CD56 chimerism. Both recipient and donor derived cells in
MC patients produced cytokines to the same degree in
response to mitogen stimulation. No difference in mitogen
response was observed between the groups.
Discussion: Long-term MC does not appear to negatively
affect the wellbeing of the patients. It could even be argued
that the recipient system has a more differentiated pheno-
type than the donor system, indicating that MC might be of
beneﬁt protecting against infections. The recipient immune
system may still be functional in MC patients, as both
recipient and donor derived cells responded to mitogens.
Two scenarios could explain such a symbiotic relationship
between donor and recipient system: a superﬂuous duplicity
of the entire immune system or an adjuvant role by the
recipient system to the donor system.236
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Development, Bethesda, MDFigure.In caring for female patients undergoing hematopoietic stem
cell transplant (HSCT), it is important to consider all aspects of
reproductive health from fertility to contraception to sexu-
ality and quality of life. Individual counseling on future
fertility is part of routine pre-transplant care. Given the var-
iable urgency with which a HSCT is undertaken and a pa-
tient’s fertility desires, fertility preservation needs and
options will vary from patient to patient. Additionally in
reproductive-age women, it is important to achieve thera-
peutic amenorrhea as well as provide effective contraception
during the HSCT process given the iatrogenic thrombocyto-
penia and exposure to potential teratogenic agents. Hormonal
therapies such as gonadotropin-releasing hormone agonists
(GnRHa), combined contraceptives, and progestin-only
methods initiated prior to transplant can each provide con-
traceptive and non-contraceptive beneﬁts for pre-meno-
pausal women. In particular, GnRHa are shown to be highly
effective in achieving therapeutic amenorrhea, especially
when started two to four weeks prior to the conditioning
regimen. Often, a single three-month dose achieves amen-
orrhea from the pre-HSCT period through engraftment. A
potential additional beneﬁt of GnRHa may be preserving
ovarian function, especially for those undergoing reduced-
intensity conditioning, though this effect is still under
investigation. Notably, the conditioning regimen is the only
gonadotoxic part of the HSCT process. Given its effectiveness
in achieving therapeutic amenorrhea, the availability of a
three-month dose, and the potential for ovarian preservation,
initiation of GnRHa warrants consideration in all pre-meno-
pausal women prior to transplant. During the pre-transplant
evaluation, gynecologists serve as valuable consultants in
addressing the appropriate timing of initiating GnRHa for
maximal beneﬁt, future fertility, contraception, therapeutic
amenorrhea, and peri-transplant reproductive health con-
cerns. During the post-transplant period through long-term
survivorship care, gynecologists can continue to address is-
sues such as revaccination for HPV, screening for genital
cancer and chronic graft versus host disease, hormone
replacement therapy, fertility, and sexuality. Gynecologists
have a role in addressing reproductive health concerns along
the entire spectrum of care for women undergoing hemato-
poietic stem cell transplant and are critical members of the
transplant team.
